Lung-RADS v2022 報告產生器

LDCT Quality: Good Acceptable Not Acceptable

CTDIvol:mGy Total DLP:mGy*cm

Prior CT Date (Y/M/D): No prior chest CT available

Lung nodule findings related to cancer screening

詳細規範請參閱 Lung-RADS v2022

No lung nodule (無肺結節)

Positive Findings (若上方開啟則鎖定): Nodule with benign features. Lung nodule(s) (<6mm) (選填 SE: , IM: ) Juxtapleural nodule. Lung nodule(s) (≧6mm or enlarging>1.5mm or new≧4mm)

Airway nodule Subsegmental (Category 2) Segmental or more proximal

Favors secretions (Category 2) At baseline (Category 4A) Stable or growing (Category 4B)

Atypical pulmonary cyst Category 3. Lobe: (SE: , IM: ) RUL RML RLL LUL LLL Category 4A. Lobe: (SE: , IM: ) RUL RML RLL LUL LLL Category 4B. Lobe: (SE: , IM: ) RUL RML RLL LUL LLL

The pattern of lung nodules has a higher probability of metastases

Other Lung Findings (選填)

Emphysema Bronchiectasis Bronchitis/bronchiolitis Tree-in-bud pattern Centrilobular nodules Old pulmonary TB Interstitial lung disease (ILD) Other

Other Findings (選填)

Enlarged lymph nodes, location

Coronary artery calcification

LAD LCX RCA

Other significant abnormal chest findings

Other significant abnormal abdominal or neck findings

Overall recommendation

Lung-RADS v2022 Category Descriptor Category 0: Incomplete.

Prior chest CT examination being located for comparison. Part or all of lungs cannot be evaluated. Findings suggestive of an inflammatory or infectious process.

Category 1: Negative. Category 2: Benign - Based on imaging features or indolent behavior. Category 3: Probably Benign - Based on imaging features or behavior. Category 4A: Suspicious. Category 4B: Very suspicious. Category 4X: Category 3 or 4 nodules with additional features or imaging findings that increase suspicion for lung cancer.

(選填)

Modifier S: May add to category 0-4 for clinically significant or potentially clinically significant findings unrelated to lung cancer. 請至門診就診

Category	Solid Nodule	Part-Solid Nodule	Non-Solid Nodule	Management
Cat 1	No nodules, or definite benign features (complete, central, popcorn, concentric rings of calcification, fat-containing)			12-month annual screening LDCT
Cat 2	• Baseline: < 6 mm • New: < 4 mm • Unchanged: < 6 mm	• Total diameter: < 6 mm (baseline, new, or unchanged)	• < 30 mm • ≥ 30 mm and stable	12-month annual screening LDCT
Cat 3	• Baseline: 6 to < 8 mm • New: 4 to < 6 mm • Unchanged: 6 to < 8 mm	• Baseline or unchanged: total ≥ 6 mm with solid component < 6 mm • New: total diameter < 6 mm	• Baseline or new: ≥ 30 mm	6-month LDCT
Cat 4A	• Baseline: 8 to < 15 mm • New: 6 to < 8 mm • Growing: < 8 mm • Unchanged: 8 to < 15 mm	• Baseline or unchanged: total ≥ 6 mm with solid component 6 to < 8 mm • New or growing: total ≥ 6 mm with solid component < 4 mm	—	3-month LDCT; PET/CT may be considered when solid component ≥ 8 mm
Cat 4B	• Baseline: ≥ 15 mm • New or growing: ≥ 8 mm	• Solid component: ≥ 8 mm (baseline or unchanged) • New or growing: total ≥ 6 mm with solid component ≥ 4 mm	—	Diagnostic chest CT (with/without contrast), PET/CT, and/or tissue sampling

Category 0 Incomplete

Malignancy Risk: N/A Management: Comparison with prior CT, or 1–3 month follow-up LDCT

Prior CT	Prior chest CT examination being located for comparison.
Unevaluated	Lungs cannot be fully evaluated due to severe motion artifact, incomplete field of coverage, or missing key series.
Infection / Inflammation	Findings suggestive of an acute infectious or inflammatory process (e.g., new or enlarging consolidations, tree-in-bud opacities, centrilobular nodules, or ground glass). A 1–3 month follow-up LDCT or clinical evaluation is recommended.

Category 1 Negative

Malignancy Risk: < 1% Management: 12-month annual screening LDCT

No Lung Nodules	No lung nodules detected.
Definite Benign Features	Nodule(s) with specific definitely benign characteristics: complete, central, popcorn, concentric rings of calcification, or fat-containing (e.g., hamartoma).

Category 2 Benign Appearance or Behavior

Malignancy Risk: < 1% Management: 12-month annual screening LDCT

Solid Nodule	• Baseline: < 6 mm • New: < 4 mm • Unchanged: < 6 mm (or stable at 3-month CT)
Part-Solid Nodule	• Total diameter: < 6 mm (baseline, new, or unchanged)
Non-Solid Nodule (GGN)	• Total diameter: < 30 mm (baseline, new, or unchanged) • Total diameter: ≥ 30 mm and stable or slowly growing
Perifissural Nodule	Typical perifissural or juxtapleural nodule (smooth, oval or lentiform, contiguous with fissure) < 10 mm.
Airway Nodule	Subsegmental nodule, or nodule favoring secretions.
Stable Cat 3 / 4 Nodule	Category 3 or 4 nodule stable for ≥ 3 months (solid or part-solid) or unchanged for 2–3 years.

Category 3 Probably Benign

Malignancy Risk: 1% – 2% Management: 6-month LDCT

Solid Nodule	• Baseline: 6 to < 8 mm • New: 4 to < 6 mm • Unchanged: 6 to < 8 mm
Part-Solid Nodule	• Baseline or unchanged: total diameter ≥ 6 mm with solid component < 6 mm • New: total diameter < 6 mm (Lung-RADS v2022 update)
Non-Solid Nodule (GGN)	• Baseline or new: total diameter ≥ 30 mm
Atypical Pulmonary Cyst	Thin-walled cyst with growing internal/circumferential nodule, or thick-walled cyst with stable appearance.

Category 4A Suspicious

Malignancy Risk: 5% – 15% Management: 3-month LDCT; PET/CT may be considered when solid component ≥ 8 mm

Solid Nodule	• Baseline: 8 to < 15 mm • New: 6 to < 8 mm • Growing: < 8 mm (increase > 1.5 mm within 12 months) • Unchanged: 8 to < 15 mm
Part-Solid Nodule	• Baseline or unchanged: total diameter ≥ 6 mm with solid component 6 to < 8 mm • New or growing: total diameter ≥ 6 mm with solid component < 4 mm
Airway Nodule	Endobronchial nodule in segmental or more proximal airway.
Atypical Pulmonary Cyst	Thick-walled cyst with growing internal/circumferential component, or multilocular cyst with progressive nodularity.

Category 4B Very Suspicious

Malignancy Risk: > 15% Management: Diagnostic chest CT (± IV contrast), PET/CT, and/or tissue sampling

Solid Nodule	• Baseline: ≥ 15 mm • New or growing: ≥ 8 mm
Part-Solid Nodule	• Solid component: ≥ 8 mm (baseline or unchanged) • New or growing: total diameter ≥ 6 mm with solid component ≥ 4 mm
Airway Nodule	Endobronchial nodule persistent on 3-month follow-up CT.
Atypical Pulmonary Cyst	Thick-walled or cavitary nodule with growing solid component.

Category 4X Very Suspicious with Additional Features

Malignancy Risk: > 15% Management: Diagnostic workup (contrast-enhanced CT, PET/CT, biopsy)

Additional Features	Category 3 or 4 nodules with additional imaging findings that increase suspicion of lung cancer: • Spiculated margins • Associated enlarged mediastinal or hilar lymphadenopathy • Frank pleural retraction or invasion • New or rapidly enlarging ground glass halo

Modifiers Modifiers & Definitions

S & C Modifiers

S Modifier	Significant Other Finding: Clinically significant or potentially significant non-lung cancer finding. • Cardiovascular: Severe coronary artery calcification (CAC), thoracic aortic aneurysm, pericardial effusion • Pulmonary & Chest: Interstitial lung disease (ILD), marked bronchiectasis, emphysema, pleural effusion • Extrapulmonary: Suspicious renal, adrenal, thyroid, or bone lesions
C Modifier	Prior Lung Cancer: Patient has a personal history of lung cancer returning to annual screening after completion of definitive therapy.
Growth Definition	An increase in mean diameter of > 1.5 mm within a 12-month interval.
Measurement Guidelines	Nodule size is based on the average of the longest diameter and perpendicular short-axis diameter on the same CT slice, rounded to the nearest whole millimeter.